Amendment Dated: September 27, 2007 Reply to Office Action mailed June 29, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

(Currently amended)
A compound of formula I, pharmaceutically acceptable salts thereof, or mixtures thereof:

wherein

 R^1 is an $\underline{C}_{5:1d}$ aryl, heteroaryl, substituted anyl or substituted $\underline{C}_{3:20}$ heteroaryl, wherein said aryl and heteroavyl are each independently and optionally substituted with one or more groups selected from $\underline{C}_{1:6}$ hydrocarbon, $\underline{-}NO_2$, $\underline{-}OR$, $\underline{-}Cl$, $\underline{-}F_1$, $\underline{-}F_2$, $\underline{-}CF_3$, $\underline{-}C(\underline{-}O)QH$, $\underline{-}NH_2$, $\underline{-}SH$, $\underline{-}NHR$, $\underline{-}NR_2$, $\underline{-}SR$, $\underline{-}SO_3H$, $\underline{-}SO_2R$, $\underline{-}S(\underline{-}O)R$, $\underline{-}CN$, $\underline{-}OH$, $\underline{-}C(\underline{-}O)QR$, $\underline{-}C(\underline{-}O)NR_2$, $\underline{-}NRC(\underline{-}O)R$, oxo ($\underline{-}O$), mino ($\underline{-}NR$), thio ($\underline{-}S$), and oximino ($\underline{-}N-OR$), wherein each R is a $C_{1:4}$ hydrocarbyl: and R^2 is hydrogen, eptionally substituted $C_{1:12}$ alkyl, applicably substituted $C_{2:12}$ heterocyclyl, wherein said alkyl, aryl, and heterocyclyl are each independently and optionally substituted with one or more groups selected from $C_{1:6}$ hydrocarbon, $\underline{-}NO_2$, $\underline{-}OR$, $\underline{-}C$, $\underline{-}F$, $\underline{-}CF_3$, $\underline{-}C(\underline{-}O)R$, $\underline{-}C(\underline{-}O)H$, $\underline{-}NH_2$, $\underline{-}SH$, $\underline{-}NH_2$, $\underline{-}SR$, $\underline{-}SO_3H$, $\underline{-}SO_2R$, $\underline{-}S(\underline{-}O)R$, $\underline{-}C$, $\underline{-}O$, $\underline{-}C$, $\underline{-}O$, $\underline{-}O$, $\underline{-}O$, $\underline{-}O$, and oximino ($\underline{-}N-OR$), wherein each R is a $C_{1:6}$ hydrocarbyl.

 (Original) A compound according to claim 1, wherein R¹ is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆alkoxy, chloro, fluoro, bromo, and iodo; and

Amendment Dated: September 27, 2007 Reply to Office Action mailed June 29, 2007

R2 is hydrogen or methyl.

3. (Original) A compound according to claim 1,

wherein R^1 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; and thiazolyl, optionally substituted with one or more groups selected from $C_{1:6}$ alkyl, halogenated $C_{1:6}$ alkyl, -

 NO_2 , $-CF_3$, $C_{1.6}$ alkoxy, chloro, fluoro, bromo, and iodo; and

R² is hydrogen or methyl.

4. (Original) A compound according to claim 1,

wherein R¹ is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; and thiazolyl; and R² is hydrogen or methyl.

5. (Original) A compound according to claim 1, wherein the compound is selected from:

3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-yl)methyl]benzamide;

3-{(4-[(diethylamino)carbonyl]phenyl)[4-(2-furylmethyl)-piperazin-1-yl]methyl}benzamide;

3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]-N-methyl-benzamide; enantiomers thereof; and pharmaceutically acceptable salts thereof.

6-7. (Cancelled)

8. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

 (currently amended) A method for the therapy of pain in a warm-blooded animal, comprising the-step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

10. (cancelled)

11. (Currently Amended) A process for preparing a compound of formula II,

Amendment Dated: September 27, 2007 Reply to Office Action mailed June 29, 2007

comprising of the step of reacting a compound of formula III:

with R¹-CHO to form the compound of formula II wherein

 R^1 is an $\underline{C}_{5:14}$ aryl, heteroaryl, substituted aryl or substituted $\underline{C}_{3:20}$ heteroaryl, wherein said aryl and heteroayl are each independently and optionally substituted with one or more groups selected from $\underline{C}_{1:6}$ hydrocarbon, $\underline{-NO}_2$, $\underline{-OR}$, $\underline{-Cl}$, $\underline{-Br}$, $\underline{-F}$, $\underline{-CF}_3$, $\underline{-C}(\underline{-O})R$, $\underline{-C}(\underline{-O})H$, $\underline{-NH}_2$, $\underline{-NH}$, $\underline{-NH}_2$, $\underline{-SR}$, $\underline{-SO}_3H$, $\underline{-SO}_2R$, $\underline{-S}(\underline{-O})R$, $\underline{-Cl}$, $\underline{-OH}$, $\underline{-C}(\underline{-O})RR$, $\underline{-C}(\underline{-O})RR$, $\underline{-NRC}(\underline{-O})R$, oxo ($\underline{-O}$), imino ($\underline{-NR}$), thio ($\underline{-S}$), and oximino ($\underline{-N-OR}$), wherein each R is a $\underline{C}_{1:6}$ hydrocarbyl.

12. (Currently Amended) A process for preparing a compound of formula IV,

Amendment Dated: September 27, 2007 Reply to Office Action mailed June 29, 2007

comprising: reacting a compound of formula II,

with an akali metal hydroxide in non-aqueous solvent to form the compound of formula IV: wherein

 R^1 is an C_{S-1g} aryl, heterearyl, substituted anyl or substituted $C_{3:20}$ heteroaryl, wherein said anyl and heteroayl are each independently and optionally substituted with one or more groups selected from $C_{1:6}$ hydrocarbon, $-NO_2$, -OR, -Cl, -Br, -l, -F, $-CF_3$, -C(=O)R, -C(=O)OH, $-NH_2$, -SH, -NHR, $-NR_2$, -SR, $-SO_3H$, $-SO_2R$, -S(=O)R, -CN, -OH, -C(=O)OR, $-C(=O)NR_2$, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each R is a $C_{1:6}$ hydrocarbyl.